Inactivated Rabies-vectored SARS-CoV-2 Vaccine Provides Long-term Immune Response Unaffected by Vector Immunity

Overview

Journal NPJ Vaccines

Date 2022 Sep 23

PMID 36151100

Authors

Catherine Yankowski

Christoph Wirblich

Drishya Kurup

Matthias J Schnell

Affiliations

Soon will be listed here.

Abstract

The objective of this study is to further analyze recombinant rabies virus-vectored SARS-CoV-2 vaccine, CORAVAX, as an effective COVID-19 vaccine strategy. CORAVAX has proven immunogenic and protective against SARS-CoV-2 in animal models. Here, we have screened adjuvants for the highest quality antibody titers, negated the concern of pre-existing rabies-vector immunity, and established its potential as a long-term COVID-19 vaccine. We have tested toll-like receptor 4 (TLR4) agonists, inflammasome activators, and alum adjuvants in CORAVAX and found TLR4-activating MPLA-AddaVax to have the greatest potential. We followed the humoral immune response to CORAVAX in mice with pre-existing rabies virus immunity and saw no significant differences compared to naive mice. We then followed the immune response to CORAVAX over several months and 1-year post-immunization. Mice maintained high antigen-specific serum antibody titers as well as long-lived antibody-secreting cells in the spleen and bone marrow. We believe this rabies-vector strategy combats the problem of waning immunity of other COVID-19 vaccines. These results together support CORAVAX's potential during the ongoing COVID-19 pandemic.

Citing Articles

Establishment of Recombinant Gene Rabies Virus SRV and Identification of Its Biological Characteristics.

Yang Y, Hou M, Su G, Ma X, Su X, Li K Viruses. 2025; 17(1).

PMID: 39861819 PMC: 11769458. DOI: 10.3390/v17010030.

Rabies virus as vector for development of vaccine: pros and cons.

Li Y, Zhou H, Li Q, Duan X, Liu F Front Vet Sci. 2024; 11:1475431.

PMID: 39386254 PMC: 11461460. DOI: 10.3389/fvets.2024.1475431.

Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease.

Scher G, Yankowski C, Kurup D, Josleyn N, Wilkinson E, Wells J NPJ Vaccines. 2024; 9(1):143.

PMID: 39122759 PMC: 11315998. DOI: 10.1038/s41541-024-00930-z.

The Development of a Rabies Virus-Vectored Vaccine against , Targeting BBI39.

Rios S, Bhattachan B, Vavilikolanu K, Kitsou C, Pal U, Schnell M Vaccines (Basel). 2024; 12(1).

PMID: 38250891 PMC: 10820992. DOI: 10.3390/vaccines12010078.

Long-term immune response to Omicron-specific mRNA vaccination in mice, hamsters, and nonhuman primates.

Wu Y, Wu N, Jia X, Wu Y, Zhang X, Liu Y MedComm (2020). 2023; 4(6):e460.

PMID: 38107058 PMC: 10724501. DOI: 10.1002/mco2.460.

References

Faber M, Faber M, Papaneri A, Bette M, Weihe E, Dietzschold B . A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity. J Virol. 2005; 79(22):14141-8. PMC: 1280225. DOI: 10.1128/JVI.79.22.14141-14148.2005. View

Khoury J, Najjar-Debbiny R, Hanna A, Jabbour A, Abu Ahmad Y, Saffuri A . COVID-19 vaccine - Long term immune decline and breakthrough infections. Vaccine. 2021; 39(48):6984-6989. PMC: 8556595. DOI: 10.1016/j.vaccine.2021.10.038. View

Rupprecht C, Nagarajan T, Ertl H . Current Status and Development of Vaccines and Other Biologics for Human Rabies Prevention. Expert Rev Vaccines. 2016; 15(6):731-49. DOI: 10.1586/14760584.2016.1140040. View

Keshwara R, Shiels T, Postnikova E, Kurup D, Wirblich C, Johnson R . Rabies-based vaccine induces potent immune responses against Nipah virus. NPJ Vaccines. 2019; 4:15. PMC: 6465360. DOI: 10.1038/s41541-019-0109-5. View

Keshwara R, Hagen K, Abreu-Mota T, Papaneri A, Liu D, Wirblich C . A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model. J Virol. 2018; 93(6). PMC: 6401435. DOI: 10.1128/JVI.01865-18. View

Edridge A, Kaczorowska J, Hoste A, Bakker M, Klein M, Loens K . Seasonal coronavirus protective immunity is short-lasting. Nat Med. 2020; 26(11):1691-1693. DOI: 10.1038/s41591-020-1083-1. View

Strady A, LANG J, Lienard M, Blondeau C, Jaussaud R, Plotkin S . Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy. J Infect Dis. 1998; 177(5):1290-5. DOI: 10.1086/515267. View

Kurup D, Wirblich C, Ramage H, Schnell M . Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2. NPJ Vaccines. 2020; 5:98. PMC: 7568577. DOI: 10.1038/s41541-020-00248-6. View

Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attlan M . Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015; 9(4):e0003709. PMC: 4400070. DOI: 10.1371/journal.pntd.0003709. View

10.

Naaber P, Tserel L, Kangro K, Sepp E, Jurjenson V, Adamson A . Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021; 10:100208. PMC: 8418937. DOI: 10.1016/j.lanepe.2021.100208. View

11.

Kurup D, Fisher C, Scher G, Yankowski C, Testa A, Keshwara R . Tetravalent Rabies-Vectored Filovirus and Lassa Fever Vaccine Induces Long-term Immunity in Nonhuman Primates. J Infect Dis. 2021; 224(6):995-1004. PMC: 8448432. DOI: 10.1093/infdis/jiab014. View

12.

Fausther-Bovendo H, Kobinger G . Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?. Hum Vaccin Immunother. 2014; 10(10):2875-84. PMC: 5443060. DOI: 10.4161/hv.29594. View

13.

Kurup D, Wirblich C, Feldmann H, Marzi A, Schnell M . Rhabdovirus-based vaccine platforms against henipaviruses. J Virol. 2014; 89(1):144-54. PMC: 4301098. DOI: 10.1128/JVI.02308-14. View

14.

Kurup D, Malherbe D, Wirblich C, Lambert R, Ronk A, Zabihi Diba L . Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model. PLoS Pathog. 2021; 17(3):e1009383. PMC: 8023494. DOI: 10.1371/journal.ppat.1009383. View

15.

Turner J, Kim W, Kalaidina E, Goss C, Rauseo A, Schmitz A . SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature. 2021; 595(7867):421-425. DOI: 10.1038/s41586-021-03647-4. View

16.

Scher G, Schnell M . Rhabdoviruses as vectors for vaccines and therapeutics. Curr Opin Virol. 2020; 44:169-182. PMC: 8331071. DOI: 10.1016/j.coviro.2020.09.003. View

17.

Blaney J, Wirblich C, Papaneri A, Johnson R, Myers C, Juelich T . Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol. 2011; 85(20):10605-16. PMC: 3187516. DOI: 10.1128/JVI.00558-11. View

18.

Johnson R, Kurup D, Hagen K, Fisher C, Keshwara R, Papaneri A . An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models. J Infect Dis. 2016; 214(suppl 3):S342-S354. PMC: 5050469. DOI: 10.1093/infdis/jiw231. View

19.

Mistry P, Barmania F, Mellet J, Peta K, Strydom A, Viljoen I . SARS-CoV-2 Variants, Vaccines, and Host Immunity. Front Immunol. 2022; 12:809244. PMC: 8761766. DOI: 10.3389/fimmu.2021.809244. View

20.

Abreu-Mota T, Hagen K, Cooper K, Jahrling P, Tan G, Wirblich C . Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever. Nat Commun. 2018; 9(1):4223. PMC: 6181965. DOI: 10.1038/s41467-018-06741-w. View